PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
HOUSTON -- Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor. A pooled ...
Zacks Investment Research on MSN
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Bristol Myers Squibb BMY announced positive data from the late-stage study on iberdomide in patients with relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback